{"pub": "reuters", "url": "https://reuters.com/article/us-spark-m-a-roche-hldg/roche-extends-spark-offer-again-as-regulatory-review-drags-on-idUSKBN1WF0EP", "downloaded_at": "2019-09-30 05:30:23.083284+00:00", "title": "Roche extends Spark offer again as regulatory review drags on", "language": "en", "text": "FILE PHOTO: The logo of Swiss drugmaker Roche at its headquarters in Basel, Switzerland, February 1, 2018. REUTERS/Arnd Wiegmann\n\nZURICH (Reuters) - Roche (ROG.S) extended its offer to buy Spark Therapeutics (ONCE.O) on Monday, this time until Oct. 30, as U.S. and British regulators continue to scrutinize the Swiss drugmaker\u2019s $4.3 billion oft-delayed bid to swallow the U.S. gene therapy specialist.\n\nThe terms and conditions remain unchanged for the deal, which analysts have said may be hung up on competition concerns over what a combination would mean for the very competitive market for hemophilia A treatments. Roche has declined to comment on what is holding back the U.S. Federal Trade Commission from signing off on the transaction.", "description": "Roche extended its offer to buy Spark Therapeutics on Monday, this time until Oct. 30, as U.S. and British regulators continue to scrutinize the Swiss drugmaker's $4.3 billion oft-delayed bid to swallow the U.S. gene therapy specialist.", "authors": ["Reuters Editorial", "Min Read"], "top_image": "https://s4.reutersmedia.net/resources/r/?m=02&d=20190930&t=2&i=1435408860&w=1200&r=LYNXMPEF8T08W", "published_at": "2019-09-30"}